Skip to search formSkip to main contentSkip to account menu

AJM300

National Institutes of Health

Related topics

Related topics

3 relations

Broader (2)

PhenylalanineQuinazolinones
analogs & derivatives

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2020
2020
AJM300, a novel oral antagonist of α4‐integrin, sustains an increase in circulating lymphocytes: A randomised controlled trial in healthy male subjects
AJM300 is an oral antagonist of α4‐integrin that reduces inflammation by blocking leucocyte trafficking. This study aimed to… 
Review
2019
Review
2019
Novel Non-biologic Targets for Inflammatory Bowel Disease
Purpose of ReviewThe biologic era revolutionized the medical management of inflammatory bowel disease (IBD) and allowed for a… 
Review
2018
Review
2018
α4β7 integrin inhibitors: a patent review
ABSTRACT Introduction: The α4β7 integrin is heterodimeric cell surface receptors expressed on most leukocytes. Mucosal addressing… 
Review
2017
Review
2017
Emerging oral targeted therapies in inflammatory bowel diseases: opportunities and challenges
To improve quality of life and prevent long-term risks in patients with inflammatory bowel diseases (IBDs: Crohn’s disease… 
Review
2016
Review
2016
Recent trends and future directions for the medical treatment of ulcerative colitis
Recently, several medical treatments for ulcerative colitis (UC) have been developed, including 5-aminosalicylic acids (5-ASAs… 
Highly Cited
2015
Highly Cited
2015
Safety and Efficacy of AJM300, an Oral Antagonist of α4 Integrin, in Induction Therapy for Patients With Active Ulcerative Colitis.
BACKGROUND & AIMS AJM300 is an orally active small-molecule antagonist of the α4 integrin subunit. We performed a randomized… 
2014
2014
370 AJM300, an Oral α4 Integrin Antagonist, for Active Ulcerative Colitis: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 2A Study
Highly Cited
2013
Highly Cited
2013
Oral treatment with a novel small molecule alpha 4 integrin antagonist, AJM300, prevents the development of experimental colitis in mice.
2012
2012
A novel, orally active alpha 4 integrin antagonist, AJM300 prevents the development of experimental colitis induced by adoptive transfer of IL-10 deficient CD4(+) T cells in mice.
Abstract Inhibition of lymphocyte trafficking by treatment with an antibody to α4 integrin has been clinically validated as a… 
Highly Cited
2009
Highly Cited
2009
S1066 Oral Alpha-4 Integrin Inhibitor (AJM300) in Patients with Active Crohn's Disease — A Randomized, Double-Blind, Placebo-Controlled Trial
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)